cta-logo01
Oncology
Menu
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Investment
  • Sectors
    • Clinical Trials
    • Approvals
    • Clinical Research
    • Operations
    • Outsourcing
    • Supply Chain
    • Cold Chain
    • Data Management
    • Medical Devices
  • Deals
  • Tech
  • Disruption
  • Coronavirus
Partners
  • Accelerating Clinical Trials
  • Simplifying Clinical Trials
Tools
  • Companies
    • Company A-Z
    • Company Categories
    • Product & Services
    • Company Releases
    • White Papers
    • Videos
  • Awards
  • Events
  • Magazine
The Company
  • About Us
  • Contact Us
  • Advertise With Us
  • Visit GlobalData
  • Login
  • Register
  • Login
  • Register
Oncology
Latest Oncology
  • Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase…
    21 hours
  • Therapy area trends for disrupted clinical trials by Covid-19
    2 days
  • Arcus’ Phase Ib/II etrumadenant has intriguing mechanism for 1L pancreatic cancer but kinks need to…
    3 days
  • LoA Update: BMS’ Opdivo LoA score drops by 13 points in endometrial cancer following investigator-led…
    3 days
  • Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase…
    21 hours
  • Therapy area trends for disrupted clinical trials by Covid-19
    2 days
  • Arcus’ Phase Ib/II etrumadenant has intriguing mechanism for 1L pancreatic cancer but kinks need to…
    3 days
  • LoA Update: BMS’ Opdivo LoA score drops by 13 points in endometrial cancer following investigator-led…
    3 days
Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase Ib
Clinical Trials

Argenx’s cusatuzumab in previously untreated AML draws varied expert forecasts for safety potential in Phase Ib

No new safety concerns coming out of Phase Ib trial desired to move forward Moving to Phase II, triplet needs…

24 Feb 2021

Top 5 Most Read

Comment 19 hours

South African Phase IIIb study of J&J’s single-jab Covid-19 vaccine enrols 18,000 participants in first week

1
News 2 days

Yale announces new trial to reduce Covid-19 complications with new therapy combo

2
AI 2 weeks

InSilicoTrials: accelerating the uptake of simulation in clinical research

3
News 2 weeks

Galapagos and Gilead Sciences to halt Phase III IPF trials

4
News 2 weeks

Janssen combination treatment meets primary endpoint in cancer trial

5

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Join Our Newsletter

Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Company A-Z

View All

Company Releases

View All

White Papers

View All

Videos

View All
CTArena_white-logo_

Powered by Pharma Tech Logo

  • About Us
  • Editorial Approach
  • Contact Us
  • Terms and Conditions
  • Privacy Policy

© Copyright 2021 Verdict Media Limited.

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more